1.Sales and profit
See section β- PharmaCyte Biotech, Inc. had $0.0M of revenue in fiscal 2026.
- PharmaCyte Biotech, Inc. lost $19.4M in fiscal 2026.
PharmaCyte Biotech, Inc.
PMCB Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2026
PharmaCyte Biotech, Inc. had $0.0M of revenue in fiscal 2026.
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$0.36
1.5%
Charts by
KIRAβs summary AI analyst
Hi! I read PharmaCyte Biotech, Inc.βs latest annual report (fiscal 2026). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- PharmaCyte Biotech, Inc. returned $0.4M to shareholders in fiscal 2026. The diluted share count rose 14.3%.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- PharmaCyte Biotech, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
PharmaCyte Biotech, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$19.4M
No. It lost money last year.
Weak
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2026
Market cap
Last close times the latest diluted share count, so it is approximate.
$3.8M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$2.08 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days PharmaCyte Biotech, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
December 17, 2026
Thursday Β· in 53 days
- Time
- Time not announced
- Covers
- Period ended Oct 31, 2026
- Source
- Earnings calendar
No past results dates on file yet.
Revenue and margins
KIRA Β· PharmaCyte Biotech, Inc. had $0.0M of revenue in fiscal 2026.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $0.0M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
FY26
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
Q3 '26
Revenue $0.0M
Q4 '26
Revenue $0.0M
Q1 '27
Revenue $0.0M
FY17
Gross β
Operating β
Net β
FCF β
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
FY26
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· PharmaCyte Biotech, Inc. lost $19.4M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
FY17
Net income β$4.4M
FY18
Net income β$6.8M
FY19
Net income β$4.1M
FY20
Net income β$3.8M
FY21
Net income β$3.6M
FY22
Net income β$4.2M
FY23
Net income β$4.3M
FY24
Net income $0.3M
FY25
Net income $30.7M
FY26
Net income β$19.4M
Q2 '24
Net income $2.8M
Q3 '24
Net income β$0.6M
Q4 '24
Net income $1.3M
Q1 '25
Net income $23.4M
Q2 '25
Net income β$1.5M
Q3 '25
Net income β$3.0M
Q4 '25
Net income $11.7M
Q1 '26
Net income β$8.4M
Q2 '26
Net income β$7.4M
Q3 '26
Net income $0.7M
Q4 '26
Net income β$4.4M
Q1 '27
Net income β$5.1M
FY17
Diluted EPS β$0.01
FY18
Diluted EPS β$0.01
FY19
Diluted EPS $0.00
FY20
Diluted EPS β$4.23
FY21
Diluted EPS β$2.45
FY22
Diluted EPS β$0.27
FY23
Diluted EPS β$0.22
FY24
Diluted EPS β$1.80
FY25
Diluted EPS $3.19
FY26
Diluted EPS β$2.77
Q2 '24
Diluted EPS β$0.26
Q3 '24
Diluted EPS β$0.65
Q4 '24
Diluted EPS β$0.35
Q1 '25
Diluted EPS $1.90
Q2 '25
Diluted EPS β$0.39
Q3 '25
Diluted EPS β$0.44
Q4 '25
Diluted EPS $2.12
Q1 '26
Diluted EPS β$1.23
Q2 '26
Diluted EPS β$1.24
Q3 '26
Diluted EPS β$0.17
Q4 '26
Diluted EPS β$0.13
Q1 '27
Diluted EPS β$0.54
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
FY17
Free cash flow β
FY18
Free cash flow β
FY19
Free cash flow β
FY20
Free cash flow β
FY21
Free cash flow β
FY22
Free cash flow β
FY23
Free cash flow β
FY24
Free cash flow β
FY25
Free cash flow β
FY26
Free cash flow β
FY17
Cash from operations β$3.3M
Capital spending β
FY18
Cash from operations β$5.1M
Capital spending β
FY19
Cash from operations β$2.9M
Capital spending β
FY20
Cash from operations β$2.3M
Capital spending β
FY21
Cash from operations β$3.3M
Capital spending β
FY22
Cash from operations β$4.1M
Capital spending β
FY23
Cash from operations β$3.8M
Capital spending β
FY24
Cash from operations β$2.2M
Capital spending β
FY25
Cash from operations β$3.0M
Capital spending β
FY26
Cash from operations β$5.2M
Capital spending β
Cash from operations
Capital spending
Q2 '24
Cash from operations β$2.0M
Capital spending β
Q3 '24
Cash from operations β$0.2M
Capital spending β
Q4 '24
Cash from operations β$0.3M
Capital spending β
Q1 '25
Cash from operations β$0.4M
Capital spending β
Q2 '25
Cash from operations β$1.1M
Capital spending β
Q3 '25
Cash from operations β$0.5M
Capital spending β
Q4 '25
Cash from operations β$1.0M
Capital spending β
Q1 '26
Cash from operations β$2.0M
Capital spending β
Q2 '26
Cash from operations β$1.0M
Capital spending β
Q3 '26
Cash from operations β$0.8M
Capital spending β
Q4 '26
Cash from operations β$1.4M
Capital spending β
Q1 '27
Cash from operations β$0.8M
Capital spending β
Cash from operations
Capital spending
Dividends, buybacks and share count
KIRA Β· PharmaCyte Biotech, Inc. returned $0.4M to shareholders in fiscal 2026. The diluted share count rose 14.3%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks $0.0M
FY23
Dividends β
Buybacks $13.6M
FY24
Dividends β
Buybacks $28.2M
FY25
Dividends β
Buybacks $2.5M
FY26
Dividends β
Buybacks $0.4M
Dividends
Buybacks
Q2 '24
Dividends β
Buybacks $0.2M
Q3 '24
Dividends β
Buybacks $0.4M
Q4 '24
Dividends β
Buybacks $1.2M
Q1 '25
Dividends β
Buybacks $0.7M
Q2 '25
Dividends β
Buybacks $1.4M
Q3 '25
Dividends β
Buybacks $0.2M
Q4 '25
Dividends β
Buybacks $0.2M
Q1 '26
Dividends β
Buybacks $0.0M
Q2 '26
Dividends β
Buybacks $0.0M
Q3 '26
Dividends β
Buybacks $0.4M
Q4 '26
Dividends β
Buybacks $0.0M
Q1 '27
Dividends β
Buybacks β
Dividends
Buybacks
FY17
Diluted shares 0.85B
FY18
Diluted shares 0.97B
FY19
Diluted shares 1.10B
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.02B
FY23
Diluted shares 0.02B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.01B
FY26
Diluted shares 0.01B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably PharmaCyte Biotech, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
FY17
Cash $3.5M
Debt β
FY18
Cash $1.1M
Debt β
FY19
Cash $0.5M
Debt β
FY20
Cash $0.9M
Debt β
FY21
Cash $2.2M
Debt β
FY22
Cash $85.4M
Debt β
FY23
Cash $68.0M
Debt β
FY24
Cash $50.2M
Debt β
FY25
Cash $15.5M
Debt β
FY26
Cash $18.9M
Debt β
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $85.4M | $68.0M | $50.2M | $15.5M | $18.9M |
| Interest coverage | β8,784.0x | β | β | β | β |
| Current ratio | 121.4x | 116.2x | 6.8x | 7.7x | 45.3x |
| Quick ratio | 121.4x | 116.2x | 6.8x | 7.7x | 45.3x |
| Total assets | $90.6M | $73.3M | $59.9M | $55.2M | $46.8M |
| Total liabilities | $0.7M | $0.6M | $20.4M | $3.3M | $11.8M |
| Shareholders' equity | $89.9M | $72.7M | $27.6M | $51.9M | $33.3M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
FY17
Return on capital β
Return on equity β54.9%
Return on assets β51.3%
FY18
Return on capital β
Return on equity β98.6%
Return on assets β90.6%
FY19
Return on capital β
Return on equity β75.3%
Return on assets β66.7%
FY20
Return on capital β
Return on equity β75.6%
Return on assets β64.1%
FY21
Return on capital β
Return on equity β60.4%
Return on assets β52.3%
FY22
Return on capital β
Return on equity β8.8%
Return on assets β8.6%
FY23
Return on capital β
Return on equity β5.3%
Return on assets β5.3%
FY24
Return on capital β
Return on equity 0.7%
Return on assets 0.5%
FY25
Return on capital β
Return on equity 77.1%
Return on assets 53.3%
FY26
Return on capital β
Return on equity β45.6%
Return on assets β38.1%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· PharmaCyte Biotech, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 7 | 2 / 7 | 4 / 7 | 3 / 7 | 3 / 7 | 1 / 7 | 3 / 7 | 4 / 7 | 2 / 7 |
| Accruals ratio | β12.7% | β23.2% | β19.5% | β24.9% | β3.2% | β0.2% | β0.6% | 3.7% | 58.5% | β28.0% |
| Altman Z'' | β20.09 | β46.04 | β54.14 | β54.11 | β39.53 | 135.83 | 130.41 | β1.11 | 13.39 | β0.16 |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $1.2M | $2.0M | $0.5M | $0.3M | $0.9M | $0.7M | $0.5M | $0.4M | $0.4M | $0.4M |
| Operating income | β$4.4M | β$7.0M | β$4.1M | β$3.8M | β$3.6M | β$4.4M | β$6.5M | β$8.5M | β$4.4M | β$6.9M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β |
| Pretax income | β | β | β | β | β | β | β | β | $30.7M | β$19.4M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$4.4M | β$6.8M | β$4.1M | β$3.8M | β$3.6M | β$4.2M | β$4.3M | $0.3M | $30.7M | β$19.4M |
| Net income to common | β | β | β | β | β | β | β$4.3M | β$17.2M | $23.4M | β$23.2M |
| Diluted EPS | β$0.01 | β$0.01 | $0.00 | β$4.23 | β$2.45 | β$0.27 | β$0.22 | β$1.80 | $3.19 | β$2.77 |
| Diluted shares | 0.85B | 0.97B | 1.10B | 0.00B | 0.00B | 0.02B | 0.02B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$3.3M | β$5.1M | β$2.9M | β$2.3M | β$3.3M | β$4.1M | β$3.8M | β$2.2M | β$3.0M | β$5.2M |
| Stock-based compensation | $0.4M | $0.6M | $0.3M | $0.4M | $0.2M | $0.0M | $0.0M | $0.7M | $0.0M | $0.9M |
| Share buybacks | β | β | β | β | β | $0.0M | $13.6M | $28.2M | $2.5M | $0.4M |
| Dividends and buybacks | β | β | β | β | β | $0.0M | $13.6M | $28.2M | $2.5M | $0.4M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.5M | $1.1M | $0.5M | $0.9M | $2.2M | $85.4M | $68.0M | $50.2M | $15.5M | $18.9M |
| Current assets | $3.5M | $1.3M | $0.7M | $1.0M | $2.3M | $85.5M | $68.1M | $50.4M | $22.4M | $37.4M |
| Current liabilities | $0.6M | $0.6M | $0.7M | $1.0M | $0.7M | $0.7M | $0.6M | $7.4M | $2.9M | $0.8M |
| Intangible assets | β | β | β | β | β | $3.5M | $3.5M | $1.5M | $1.5M | $0.0M |
| Total assets | $8.7M | $6.4M | $5.8M | $6.2M | $7.4M | $90.6M | $73.3M | $59.9M | $55.2M | $46.8M |
| Total liabilities | $0.6M | $0.6M | $0.7M | $1.1M | $0.7M | $0.7M | $0.6M | $20.4M | $3.3M | $11.8M |
| Preferred stock | β | β | $0.0M | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $8.1M | $5.8M | $5.0M | $5.1M | $6.7M | $89.9M | $72.7M | $27.6M | $51.9M | $33.3M |
| Returns | ||||||||||
| Return on capital employed | β54.9% | β121.0% | β81.4% | β74.5% | β54.2% | β4.9% | β8.9% | β16.2% | β8.4% | β14.9% |
| Return on equity | β54.9% | β98.6% | β75.3% | β75.6% | β60.4% | β8.8% | β5.3% | 0.7% | 77.1% | β45.6% |
| Return on assets | β51.3% | β90.6% | β66.7% | β64.1% | β52.3% | β8.6% | β5.3% | 0.5% | 53.3% | β38.1% |
| Return on tangible equity | β54.9% | β118.4% | β80.7% | β75.2% | β53.2% | β4.9% | β6.2% | β66.0% | 46.4% | β69.7% |
| Growth | ||||||||||
| Net income growth | β | β | β | β | β | β | β | β | 9,084.0% | β163.4% |
| EPS growth | β | β | β | β | β | β | β | β | β | β186.8% |
| Share count change | β | 14.6% | 13.6% | β99.9% | 60.2% | 971.7% | 25.6% | β50.8% | β23.5% | 14.3% |
| Financial health | ||||||||||
| Interest coverage | β2,961.4x | β | β | β7,652.8x | β1,207.7x | β8,784.0x | β | β | β | β |
| Current ratio | 6.1x | 2.0x | 0.9x | 1.0x | 3.1x | 121.4x | 116.2x | 6.8x | 7.7x | 45.3x |
| Quick ratio | 6.1x | 2.0x | 0.9x | 1.0x | 3.1x | 121.4x | 116.2x | 6.8x | 7.7x | 45.3x |
| Quality scores | ||||||||||
| Piotroski F-score | β | 1.0 | 2.0 | 4.0 | 3.0 | 3.0 | 1.0 | 3.0 | 4.0 | 2.0 |
| Altman Z'' | β20.1 | β46.0 | β54.1 | β54.1 | β39.5 | 135.8 | 130.4 | β1.1 | 13.4 | β0.2 |
| Accruals ratio | β12.7% | β23.2% | β19.5% | β24.9% | β3.2% | β0.2% | β0.6% | 3.7% | 58.5% | β28.0% |
Source: SEC EDGAR XBRL filings (CIK 0001157075). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.